- Advancing to first-in-human dosing of CYB004, a proprietary deuterated DMT molecule - - CYB004 being developed to provide less invasive and more convenient dosing methods as compared with IV infused DMT - - Phase 1 topline data expected in Q3 2023 -TOR
First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS® (voclosporin) Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms fro
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESSASKATOON, Saskatchewan & LONDON--(BUSINESS WIRE)--Gensource Potash Corporation (“Gensource” or the “Company”) (AIM/TSXV: GSP), a fertilizer development company
OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA t
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (TSX: AFN) (“AGI”, the “Company”, “we” or “our”) today announced its financial results for the three-months ended March 31, 2023. First Quarter 2023 Highlights Record first
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platfor
TORONTO--(BUSINESS WIRE)--$HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the tr
Funding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESHALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TS
Kinaxis becomes the first vendor to occupy the furthest positions on both axes in the report, which it believes reinforces its continued delivery of proven business value for supply chain resiliency and agilityOTTAWA--(BUSINESS WIRE)--Kinaxis® Inc. (TSX
Total revenue of $12 million, compared to $317 million in Q1 2022 Total cumulative partnered program starts of 101, up 20% from Q1 2022 Net loss of $0.14 per share on a basic and diluted basis, compared to net earnings of $0.59 (basic) and $0.54 (dilu
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.